Orchestra BioMed (OBIO) Insider Purchase: 3,000 Shares Disclosed

Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. (OBIO) reporting person Darren Sherman, identified as President and Chief Operating Officer, acquired 3,000 shares of the company's common stock on 08/25/2025 at a price of $2.62 per share. Following the transaction, Mr. Sherman directly beneficially owns 926,837 shares. The Form 4 was signed by an attorney-in-fact.

Positive

• Insider acquisition disclosed: 3,000 shares purchased at $2.62 per share
• Clear role identified: Reporting person is President and Chief Operating Officer
• Post-transaction ownership disclosed: 926,837 shares beneficially owned (direct)

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider purchase of 3,000 shares by the COO is a routine Form 4 disclosure with limited market impact.

The filing documents a small open-market acquisition by a senior executive: 3,000 shares at $2.62 each, raising direct beneficial ownership to 926,837 shares. This is a factual disclosure of insider activity without accompanying material corporate events, financial results, or changes to outstanding equity that would alter valuation materially.

Corporate Governance Expert

TL;DR: Disclosure meets Section 16 reporting requirements; transaction appears properly documented and signed by an attorney-in-fact.

The Form 4 identifies the reporting person, role (President and COO), transaction details, and the post-transaction ownership amount. The signature block shows an attorney-in-fact executed the form. No amendments or additional governance actions are reported in this filing.

Insider Trade Summary

Net Buyer: 3,000 shares

Net Buy 1 txn

Insider Sherman Darren

Role See Remarks

Bought 3,000 shs ($8K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share	3,000	$2.62	$8K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 926,837 shares (Direct)

FAQ

What transaction did Darren Sherman report on Form 4 for OBIO?

He reported acquiring 3,000 shares of Orchestra BioMed common stock on 08/25/2025 at $2.62 per share.

What is Darren Sherman’s role at Orchestra BioMed (OBIO)?

He is identified as President and Chief Operating Officer in the Form 4 filing.

How many OBIO shares does Darren Sherman own after the reported transaction?

He directly beneficially owns 926,837 shares following the purchase reported on the Form 4.

Was the Form 4 signed by the reporting person?

The form shows a signature executed by an attorney-in-fact (/s/ Andrew Taylor) dated 08/25/2025.

Does the Form 4 indicate an amendment or multiple filers?

No amendment date is provided and the filing indicates it was filed by one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 08/25/2025 - 07:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sherman Darren

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	08/25/2025		P		3,000	A	$2.62	926,837	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

President and Chief Operating Officer

	/s/ Andrew Taylor, Attorney-in-Fact	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.